Beam Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Beam Therapeutics

10/05/2023 13:49

* Beam Therapeutics Inc  BEAM.OQ  reported a quarterly
adjusted
loss of $1.33​​ per share for the quarter ended in March. The
mean expectation of thirteen analysts for the quarter was for a
loss of $1.34 per share.
    * Revenue rose 187.1% to $24.21 million from a year ago;
analysts
expected $14.08 million. 
    * Beam Therapeutics Inc's reported EPS for the quarter was a
loss
of $1.33​.
    * The mean earnings estimate of analysts had fallen by
about 1.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Beam Therapeutics Inc shares had risen by 12.7% this
quarter and
lost 11.8% so far this year.
    * The company reported a quarterly loss of $96.46 million.
    * Wall Street's median 12-month price target for Beam
Therapeutics
Inc is $62.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
10 at 12:49 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -1.34          -1.33          Beat
 Dec. 31 2022      -1.33          -0.54          Beat
 Sep. 30 2022      -1.31          -1.56          Missed
 Jun. 30 2022      -1.08          -1.02          Beat